| scholarly article | Q13442814 |
| P2093 | author name string | Guan Zhu | |
| Xiaomin Cai | |||
| Steve J Upton | |||
| Keith M Woods | |||
| P2860 | cites work | Complete Genome Sequence of the Apicomplexan, Cryptosporidium parvum | Q22065819 |
| The genome of Cryptosporidium hominis | Q22122489 | ||
| Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell line | Q28319303 | ||
| Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models | Q28368312 | ||
| Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum | Q28379469 | ||
| Cryptosporidium hominis n. sp. (Apicomplexa: Cryptosporidiidae) from Homo sapiens | Q30758307 | ||
| The biology of Cryptosporidium | Q34003989 | ||
| Epidemiology of Cryptosporidium: transmission, detection and identification | Q34102697 | ||
| Real‐Time Polymerase Chain Reaction | Q35581898 | ||
| Effects of select medium supplements on in vitro development of Cryptosporidium parvum in HCT-8 cells. | Q36518510 | ||
| Quantitative-PCR assessment of Cryptosporidium parvum cell culture infection. | Q40450839 | ||
| Intron-containing beta-tubulin transcripts in Cryptosporidium parvum cultured in vitro | Q40557997 | ||
| Immunohistochemistry based assay to determine the effects of treatments on Cryptosporidium parvum viability | Q40743554 | ||
| Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells | Q40869727 | ||
| Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells | Q40942214 | ||
| In vitro evaluation of anticryptosporidial agents using MDCK cell culture and chemiluminescence immunoassay | Q41171646 | ||
| A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro | Q41219998 | ||
| Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro | Q42551096 | ||
| Pyrazole, an alcohol dehydrogenase inhibitor, has dual effects on N-methyl-D-aspartate receptors of hippocampal pyramidal cells: agonist and noncompetitive antagonist | Q42598980 | ||
| What is the phylogenetic position of Cryptosporidium? | Q45314622 | ||
| Nitazoxanide: a new thiazolide antiparasitic agent | Q46404981 | ||
| Molecular analysis of a P-type ATPase from Cryptosporidium parvum | Q48039755 | ||
| Oxidation of the alcohol dehydrogenase inhibitor pyrazole to 4-hydroxypyrazole by microsomes. Effect of cytochrome P-450 inducing agents | Q69910213 | ||
| Effect of pH on pyrazole binding to liver alcohol dehydrogenase | Q70152991 | ||
| Pyrazole binding in crystalline binary and ternary complexes with liver alcohol dehydrogenase | Q71451933 | ||
| Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro | Q72221884 | ||
| Kinetic mechanism of yeast alcohol dehydrogenase activity with secondary alcohols and ketones | Q72535246 | ||
| Cryptosporidiosis | Q73247280 | ||
| Characterization of intracellular Cryptosporidium parvum gene expression | Q73253988 | ||
| The development of a real-time quantitative-PCR method for characterisation of a Cryptosporidium parvum in vitro culturing system and assessment of drug efficacy | Q74189533 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cryptosporidium parvum | Q134734 |
| P304 | page(s) | 4437-4442 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro | |
| P478 | volume | 49 |
| Q28475058 | A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase |
| Q64097700 | A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors |
| Q41741437 | A unique hexokinase in Cryptosporidium parvum, an apicomplexan pathogen lacking the Krebs cycle and oxidative phosphorylation. |
| Q40068500 | Aged HCT-8 cell monolayers support Cryptosporidium parvum infection |
| Q37671934 | Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases. |
| Q39167515 | CP2 gene as a useful viability marker for Cryptosporidium parvum |
| Q95840961 | Characterization of Calcium-Dependent Protein Kinases 3, a Protein Involved in Growth of Cryptosporidium parvum |
| Q40241688 | Characterization of Host Cell Mutants Significantly Resistant to Cryptosporidium parvum Infection |
| Q64056583 | Characterization of a Species-Specific Insulinase-Like Protease in |
| Q39864781 | Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum |
| Q28550913 | Cryptosporidium Lactate Dehydrogenase Is Associated with the Parasitophorous Vacuole Membrane and Is a Potential Target for Developing Therapeutics |
| Q90113978 | Cryptosporidium parvum gp40/15 Is Associated with the Parasitophorous Vacuole Membrane and Is a Potential Vaccine Target |
| Q30443537 | Detection and quantification of Cryptosporidium in HCT-8 cells and human fecal specimens using real-time polymerase chain reaction. |
| Q64950428 | Differential Expression of Three Cryptosporidium Species-Specific MEDLE Proteins. |
| Q36642424 | Differential Gene Expression and Protein Localization of Cryptosporidium parvum Fatty Acyl-CoA Synthetase Isoforms. |
| Q90265315 | Discovery of Novel Anti-cryptosporidial Activities From Natural Products by in vitro High-Throughput Phenotypic Screening |
| Q50136314 | Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugs |
| Q34574121 | Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth |
| Q34039880 | Efficacy of S-adenosylhomocysteine hydrolase inhibitors, D-eritadenine and (S)-DHPA, against the growth of Cryptosporidium parvum in vitro |
| Q39545463 | Efficacy of ginkgolic acids against Cryptosporidium andersoni in cell culture |
| Q34878212 | Genome-wide upstream motif analysis of Cryptosporidium parvum genes clustered by expression profile |
| Q36911475 | Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection |
| Q93088334 | Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis |
| Q34141383 | In vitro determination of anticryptosporidial activity of phytogenic extracts and compounds. |
| Q36668014 | Inactivation of protozoan parasites in food, water, and environmental systems |
| Q24289284 | Inhibition of Chikungunya Virus Replication by 1-[(2-Methylbenzimidazol-1-yl) Methyl]-2-Oxo-Indolin-3-ylidene] Amino] Thiourea(MBZM-N-IBT) |
| Q36804184 | Inhibition of apoptosis in Cryptosporidium parvum-infected intestinal epithelial cells is dependent on survivin |
| Q35944070 | Involvement of host cell integrin α2 in Cryptosporidium parvum infection |
| Q54195824 | Molecular and biochemical characterization of Eimeria tenella hexokinase. |
| Q38722957 | Novel Bioengineered Three-Dimensional Human Intestinal Model for Long-Term Infection of Cryptosporidium parvum |
| Q34100267 | Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP) |
| Q31053966 | Novel methods of quantitative real-time PCR data analysis in a murine Helicobacter pylori vaccine model. |
| Q28475422 | Plant-Type Trehalose Synthetic Pathway in Cryptosporidium and Some Other Apicomplexans |
| Q40044929 | Preliminary Characterization of MEDLE-2, a Protein Potentially Involved in the Invasion of Cryptosporidium parvum |
| Q33855150 | Prodrug activation by Cryptosporidium thymidine kinase |
| Q34720875 | Quantification of in vitro and in vivo Cryptosporidium parvum infection by using real-time PCR. |
| Q36098066 | Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro |
| Q27003233 | Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases |
| Q39607184 | Stress-induced Hsp70 gene expression and inactivation of Cryptosporidium parvum oocysts by chlorine-based oxidants |
| Q39020376 | Susceptibility Testing of Medically Important Parasites |
| Q36740182 | Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis |
| Q28481508 | The Cryptosporidium parvum transcriptome during in vitro development |
| Q64065238 | The effect of autophagy on the survival and invasive activity of Eimeria tenella sporozoites |
| Q38004333 | Therapy and prevention of cryptosporidiosis in animals |
| Q34484657 | Transcriptome analysis reveals unique metabolic features in the Cryptosporidium parvum Oocysts associated with environmental survival and stresses |
| Q37202848 | Treatment of parasitic diarrhea in HIV-infected patients |
Search more.